Terms: = Thyroid cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Clinical Outcome
173 results:
1. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
4. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
5. thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
6. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
7. The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study.
Zuhur SS; Aggul H; Avci U; Erol S; Tuna MM; Uysal S; Akbaba G; Kilinc F; Catak M; Tekin S; Ozturk BO; Yavuz HC; Kadioglu P; Cinar N; Bayraktaroglu T; Topcu B; Altuntas Y; Elbuken G
Endocrine; 2024 Mar; 83(3):700-707. PubMed ID: 37736822
[TBL] [Abstract] [Full Text] [Related]
8. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy.
Wang C; Lu G; Li Y; Liu X; Wang G; Lu C; Li J; Luo Q; Zhang Q; Sun M; Wang X; Wang R
Front Endocrinol (Lausanne); 2023; 14():1217092. PubMed ID: 37600705
[TBL] [Abstract] [Full Text] [Related]
9. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract] [Full Text] [Related]
10. No Association of Preablation Thyroglobulin Antibody Positivity and outcome in Pediatric Patients With Papillary thyroid Carcinoma.
Xu Y; Shi L; Wu J; Li H; Wang Y; Liu B
Clin Nucl Med; 2023 Sep; 48(9):763-767. PubMed ID: 37385237
[TBL] [Abstract] [Full Text] [Related]
11. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
[TBL] [Abstract] [Full Text] [Related]
12. Magnetic resonance diagnosis of laryngeal chondritis after transoral laser microsurgery for laryngeal cancer.
Cunha B; Lancini D; Rondi P; Ravanelli M; Maroldi R; Paderno A; Zigliani G; Bertotto I; Piazza C; Farina D
Acta Otorhinolaryngol Ital; 2023 Feb; 43(1):32-41. PubMed ID: 36860148
[TBL] [Abstract] [Full Text] [Related]
13. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract] [Full Text] [Related]
14. Do Histologically Aggressive Subtypes of Papillary thyroid Microcarcinoma have Worse clinical outcome than Non-Aggressive Papillary thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study.
Zuhur SS; Aggul H; Avci U; Erol S; Tuna MM; Uysal S; Akbaba G; Kilinç F; Catak M; Tekin S; Bilen OI; Öztürk BO; Erden EB; Elbuken G; Yavuz HC; Kadioglu P; Cinar N; Kutluturk F; Bayraktaroglu T; Topçu B; Arslan AI; Gucer H; Cihangiroglu G; Topal CS; Ozturk T; Tekin L; Artas G; Akcay E; Gun BD; Altuntas Y
Horm Metab Res; 2023 May; 55(5):323-332. PubMed ID: 36764327
[TBL] [Abstract] [Full Text] [Related]
15. Reclassification of papillary thyroid microcarcinoma (pMCT) according to the "Porto proposal" criteria.
Ben Rejeb S; Aloui D; Aloui M; Chouchen H; Turki S
Tunis Med; 2022 juillet; 100(7):547-550. PubMed ID: 36571744
[TBL] [Abstract] [Full Text] [Related]
16. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
17. Dacryoendoscopic Findings of Patients with Lacrimal Drainage Obstruction Associated with cancer Treatment.
Kim Y; Lew H
Korean J Ophthalmol; 2022 Dec; 36(6):509-517. PubMed ID: 36220641
[TBL] [Abstract] [Full Text] [Related]
18. clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis.
Yin L; Hou S; Hou LL; Pu CC
Endocrine; 2023 Feb; 79(2):331-341. PubMed ID: 36207552
[TBL] [Abstract] [Full Text] [Related]
19. Is multifocality a risk factor in low-risk papillary thyroid cancer?
Sapuppo G; Grasso S; Di Benedetto G; Marturano I; Costanzo G; Belfiore A; Pellegriti G
Endokrynol Pol; 2022; 73(6):928-934. PubMed ID: 36094871
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of Delayed Surgery and clinical outcomes in Intermediate- and High-risk Papillary thyroid cancer.
Zhou H; Wu J; Shi L; Wang Y; Liu B
J Clin Endocrinol Metab; 2022 Nov; 107(12):3389-3397. PubMed ID: 36056633
[TBL] [Abstract] [Full Text] [Related]
[Next]
